Get the Stockscreener App
10.96
5.60%
-0.65
After Hours:
10.85
-0.11
-1.00%
Armata Pharmaceuticals Inc stock is traded at $10.96, with a volume of 64,115.
It is down -5.60% in the last 24 hours and up +35.64% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$11.61
Open:
$11.6
24h Volume:
64,115
Relative Volume:
1.27
Market Cap:
$399.02M
Revenue:
-
Net Income/Loss:
$-41.36M
P/E Ratio:
-6.6829
EPS:
-1.64
Net Cash Flow:
$-42.09M
1W Performance:
+1.20%
1M Performance:
+35.64%
6M Performance:
+284.56%
1Y Performance:
+442.57%
1-Day Range:
$10.78
$11.66
1-Week Range:
$9.99
$11.81
52-Week Range:
$0.8981
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
10.96 | 422.68M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
ARMPAmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split - ADVFN Ltd
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX - RTTNews
ARMP Should I Buy - Intellectia AI
Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq
ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus
Armata Pharmaceuticals stock gains on FDA designation By Investing.com - Investing.com Canada
Armata Pharmaceuticals stock gains on FDA designation - Investing.com India
Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment - marketscreener.com
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy - TipRanks
Armata Pharmaceuticals receives FDA qualified infectious disease product designation - marketscreener.com
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation - TradingView
Armata Pharmaceuticals wins FDA QIDP for AP-SA02, enabling 5 years exclusivity and Fast Track eligibility - TradingView
FDA grants QIDP designation to Armata (ARMP) phage therapy AP-SA02 - Stock Titan
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire
Growth Value: What analysts say about Armata Pharmaceuticals Inc stock2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Options Flow: Is HFBL a turnaround storyMarket Volume Report & AI Driven Stock Movement Reports - baoquankhu1.vn
ARMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Increase in Short Interest - MarketBeat
Is Armata Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
MACD Signal: What analysts say about Armata Pharmaceuticals Inc stockJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - baoquankhu1.vn
Armata Pharmaceuticals FY2025 EPS Boosted by HC Wainwright - MarketBeat
Aug Closing: What is RADCOM Ltds debt to equity ratioMarket Movers & High Accuracy Swing Trade Signals - baoquankhu1.vn
AI Stocks: Can Armata Pharmaceuticals Inc grow without external fundingMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) price target increased by 33.33% to 12.24 - MSN
Phage Therapy Market Set to Witness Significant Growth - openPR.com
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Armata Pharmaceuticals (ARMP) and Halozyme (HALO) - The Globe and Mail
Armata Extends Innoviva Credit, Warrants and Voting Pact - The Globe and Mail
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 2%Time to Buy? - MarketBeat
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - MSN
Will Armata Pharmaceuticals Inc. stock gain from lower inflationQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Published on: 2026-01-19 10:14:54 - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) Price Target Increased by 33.33% to 12.24 - Nasdaq
Block Trades: Is Armata Pharmaceuticals Inc stock a smart retirement pickTrade Risk Assessment & Growth Focused Stock Pick Reports - baoquankhu1.vn
Armata Wins FDA Support to Advance Bacteriophage to Phase 3 - TipRanks
Armata Pharmaceuticals Advances AP-SA02 to Phase 3 Study - TradingView — Track All Markets
C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ – Company Announcement - Financial Times
ARMP Stock Quote - richtv.io
Why Armata Pharmaceuticals Inc. (TG1N) stock is upgraded to buyJuly 2025 Weekly Recap & Target Return Focused Picks - ulpravda.ru
What valuation multiples suggest for Armata Pharmaceuticals Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
Armata Pharmaceuticals, Inc. Common Stock (NY: ARMP - FinancialContent
Will Armata Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Trend Report & Entry and Exit Point Strategies - Улправда
Will Armata Pharmaceuticals Inc. stock continue dividend increases2025 Price Targets & Community Consensus Trade Alerts - Улправда
Trade Recap: Will Armata Pharmaceuticals Inc. stock deliver long term returnsJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Улправда
Can Armata Pharmaceuticals Inc. stock attract ESG capital inflowsMarket Risk Summary & Scalable Portfolio Growth Methods - ulpravda.ru
Will Armata Pharmaceuticals Inc. stock maintain dividend yield2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
Will Armata Pharmaceuticals Inc. stock pay special dividendsMarket Sentiment Review & Real-Time Stock Movement Alerts - Улправда
About Us | Oil & Gas JournalArmata Pharmaceuticals, Inc. Common Stock (NYSE:ARMP) Detailed Stock Data - FinancialContent
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):